Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. (NY: OGN )

17.35 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 204
Open 17.35
Bid (Size) 17.35 (1)
Ask (Size) 17.42 (1)
Prev. Close 17.35
Today's Range 17.35 - 17.35
52wk Range 10.84 - 23.10
Shares Outstanding N/A
Dividend Yield 6.46%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga

Performance

YTD
+17.95%
+17.95%
1 Month
-12.02%
-12.02%
3 Month
-19.15%
-19.15%
6 Month
-6.32%
-6.32%
1 Year
+12.08%
+12.08%

More News

Read More
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
From Organon & Co.
Via Business Wire
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
Via Benzinga
P/E Ratio Insights for Organon
Via Benzinga
3 Cheap High Dividend Stocks For Passive Income
Via Talk Markets
High Dividend 50: Organon & Co.
Via Talk Markets
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
From Organon & Co.
Via Business Wire
Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy
Via Talk Markets
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Via Benzinga
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Organon & Co.
Via Business Wire
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Via Benzinga
Organon Stock Sees Relative Strength Rating Rise To 91
Via Investor's Business Daily
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
Via Investor's Business Daily
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
From Organon & Co.
Via Business Wire
OGN Stock Earnings: Organon Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Organon Reports Results for the Second Quarter Ended June 30, 2024
From Organon & Co.
Via Business Wire
Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount'
Via Benzinga
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
From Organon & Co.
Via Business Wire
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
Via The Motley Fool
Topics ETFs
Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now
Via InvestorPlace
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Via The Motley Fool
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
From Organon & Co.
Via Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.